---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124141"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:55:45.273741+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports Q3 net loss of $2.2M; cash $6.5M into 2025

## Summary
- Net loss Q3 2024: $2.2M ($0.84 per share) vs $2.6M loss in Q3 2023; nine-month net loss $13.3M vs net income $2.1M in prior year.
- Cash and cash equivalents $6.5M as of Sep 30, 2024, down from $12.0M at Dec 31, 2023; raised $3.8M from warrant exercise in Aug 2024.
- Clinical-stage biotech advancing Gemini; expects FDA IND acceptance to start Phase 1b in CKD patients; cash runway into 2025.
- Net cash used in operations nine months: $14.6M vs $5.3M in 2023; cash burn increased significantly.

## SEC filing metadata
- accession: 0000950170-24-124141
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024124141/0000950170-24-124141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024124141/revb-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124141
- JSON: https://secwatch.observer/filing/0000950170-24-124141.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.